GLP-1 medicines and breastfeeding: the honest, careful answer
GLP-1 weight-loss medicines like semaglutide and liraglutide are generally not recommended while you are breastfeeding. The FDA labels say there are no data on these drugs in human milk, and rodent studies show the drugs do pass into animal milk. One small study of eight mothers found that injectable semaglutide was not detectable in milk, but the human data are still very limited. The Wegovy tablet form is specifically not recommended during nursing because of an extra ingredient called SNAC. The good news is that breastfeeding itself helps with postpartum weight loss and gives your baby big health benefits. This guide explains what the FDA labels, the LactMed database, and the World Health Organization really say, the postpartum weight-loss question, and the timing of when you might restart. Your doctor and your baby's pediatrician decide your care.
Many new mothers want to lose the weight they gained in pregnancy. So a GLP-1 medicine like semaglutide (Ozempic, Wegovy) or liraglutide (Saxenda) can look like an easy answer after birth. But if you are breastfeeding, a new question comes first: is the medicine safe for your baby through your milk? The honest answer is that GLP-1 medicines are generally not recommended while you are nursing. The FDA labels say there are no data on these drugs in human milk, and rodent studies show the drugs do pass into animal milk. One small study of eight mothers found that injectable semaglutide was not detectable in milk, but that is still very little human data. This guide walks through what the FDA labels, the NIH LactMed database, and the World Health Organization really say, so you can talk to your doctor and your baby's pediatrician with the facts in hand.
The baseline: no human milk data, rodent milk data, and one small study
The honest baseline starts with what the FDA drug labels say. The Ozempic (semaglutide) label states, 'There are no data on the presence of semaglutide in human milk, the effects on the breastfed infant, or the effects on milk production.' The Wegovy (semaglutide) injection label says the same: 'There are no data on the presence of subcutaneously administered semaglutide or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production.' The Saxenda (liraglutide) label is similar: 'There are no data on the presence of liraglutide in human milk, the effects on the breastfed infant, or effects on milk production.' So for all three, the human milk picture is basically unknown. What we do have is rodent data. The Ozempic label notes, 'Semaglutide was present in the milk of lactating rats,' and adds, 'In lactating rats, semaglutide was detected in milk at levels 3- to 12-fold lower than in maternal plasma.' The Saxenda label goes further: 'In lactating rats, liraglutide was present unchanged in milk at concentrations approximately 50% of maternal plasma concentrations.' So the drugs do reach animal milk, though rats and humans are not the same. There is one small human study. The NIH LactMed database reports that 'eight nursing mothers, who were using subcutaneous semaglutide in doses ranging from 0.25 to 1 mg weekly, donated milk samples at 0,12 and 24 hours after a dose,' and 'none of the samples contained any measurable semaglutide (<1.7 mcg/L).' LactMed adds that 'the relative infant dose would have averaged only 1.12%,' well below the 10% level usually seen as the safety cut-off. The study behind this, by Diab and colleagues, found that 'semaglutide was not detected in any of the collected human milk samples,' with 'the maximum RID projected was 1.26%, far below the standard 10% safety threshold.' That is reassuring, but it is only eight mothers and short-term. The labels also remind doctors to weigh the value of breastfeeding. The Wegovy label says, 'The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for WEGOVY.' In other words, breastfeeding matters a lot, and the decision to use a GLP-1 while nursing must weigh that benefit.
GLP-1 weight-loss medicines are safe to take while breastfeeding, so you can start them after birth to lose pregnancy weight.
misleadingMisleading and not supported by the labels. The FDA labels for Ozempic, Wegovy injection, and Saxenda all state there are no data on the medicine in human milk. The Ozempic label says, 'There are no data on the presence of semaglutide in human milk, the effects on the breastfed infant, or the effects on milk production.' The Saxenda label says the same about liraglutide. The Wegovy tablet label goes further and says to 'advise patients that breastfeeding is not recommended during treatment with WEGOVY tablets' because of the absorption enhancer SNAC. Animal data show the drugs do pass into rodent milk: the Saxenda label notes 'liraglutide was present unchanged in milk at concentrations approximately 50% of maternal plasma concentrations.' There is one small human study of eight mothers showing injectable semaglutide was not detected in milk, with a relative infant dose of about 1.12%, but that is a tiny sample and short-term. Because of these unknowns, the careful medical stance is that GLP-1 medicines are generally not recommended while you are nursing, and you should not start one for postpartum weight loss without your doctor and your baby's pediatrician weighing in. Breastfeeding itself also helps with postpartum weight loss, so a GLP-1 is not the only path. Your doctor and pediatrician decide.
Small tips that add up
The bottom line
GLP-1 weight-loss medicines like semaglutide and liraglutide are generally not recommended while you are breastfeeding. The FDA labels for Ozempic, Wegovy injection, and Saxenda all say there are no data on the drug in human milk. Animal data show the drugs do pass into rodent milk, with the Saxenda label noting liraglutide was present in rat milk at about 50% of maternal plasma levels. The Wegovy tablet form is specifically not recommended during nursing because of the SNAC absorption enhancer. One small study of eight mothers found injectable semaglutide was not detectable in milk, with a relative infant dose of about 1.12%, but that is very limited data. LactMed advises using liraglutide with caution during breastfeeding, especially with a newborn or preterm infant. The good news is that breastfeeding itself helps with postpartum weight loss and protects your health, so a GLP-1 is not your only path back to your pre-pregnancy weight. Do not start a GLP-1 for postpartum weight loss while nursing without your doctor and your baby's pediatrician weighing in. Burnie can help you log your food and track your daily calorie deficit, but decisions about medicines and breastfeeding belong with your doctors.